Is EW a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Edwards Lifesciences (EW) rests on TAVR leadership and label expansion: TAVR remains the core franchise, generating about $4.49 billion in 2025, up roughly 9.3% year over year, and Edwards held an estimated low-70s percent share of the U.S. The bear case rests on edwards faces several headwinds at once. Analysts covering it publish targets from $84.00 to $110.00 against a $85.35 price, so even the professionals disagree by 26% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Edwards Lifesciences designs and sells devices that treat structural heart disease, conditions where the heart's valves are damaged or diseased. Its largest business is TAVR, a minimally invasive procedure that replaces a narrowed aortic valve with the SAPIEN valve delivered through a catheter rather than open-heart surgery; TAVR generated about $4.49 billion in 2025, roughly three-quarters of company sales. The company also sells transcatheter mitral and tricuspid therapies (TMTT) such as the PASCAL repair system, EVOQUE tricuspid valve, and SAPIEN M3 mitral system, plus traditional surgical heart valves and supporting technologies. Edwards makes money by selling these high-margin implantable devices to hospitals worldwide, supported by clinical evidence and physician training that reinforce its leadership. Edwards was spun off from Baxter International in 2000 and became a pure-play structural heart company in 2024 when it divested its Critical Care monitoring business to Becton Dickinson (BD) for roughly $4.2 billion, sharpening its focus on transcatheter heart valves. Recent developments include the EARLY TAVR trial supporting treatment of asymptomatic severe aortic stenosis patients, with Edwards working toward an expanded FDA label, and about $1.2 billion of acquisitions (JenaValve for aortic regurgitation and Endotronix for heart-failure monitoring). TMTT grew more than 56% in 2025 to about $551 million, and the company has returned cash through share buybacks rather than a dividend.
The bull case: what would have to be true for $110.00
The most optimistic published target on EW is $110.00, +28.9% from the $85.35 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. TAVR leadership and label expansion.
TAVR remains the core franchise, generating about $4.49 billion in 2025, up roughly 9.3% year over year, and Edwards held an estimated low-70s percent share of the U.S. market. The EARLY TAVR trial supports treating asymptomatic severe aortic stenosis patients, and an expanded FDA indication could enlarge the eligible patient pool. Boston Scientific's 2025 exit from TAVR removed one competitor, leaving Medtronic and Abbott as the main rivals.
2. TMTT as the growth engine.
Transcatheter mitral and tricuspid therapies grew about 56% in 2025 to roughly $551 million, driven by the PASCAL repair system, EVOQUE tricuspid valve, and SAPIEN M3 mitral valve. Management guided 2026 TMTT revenue of about $740 to $780 million, implying 35% to 45% growth. This franchise is the clearest path to extending Edwards' structural-heart leadership beyond aortic valves.
3. High margins and strong cash generation.
Edwards runs gross margins near 78%, reflecting the value of differentiated implantable devices and entrenched clinical adoption. That profitability funds heavy R&D and a steady acquisition program. The company returns cash through buybacks, completing a roughly $500 million repurchase in early 2026 with about $1.5 billion remaining under authorization rather than paying a dividend.
4. Pipeline and acquisitions.
Edwards spent about $1.2 billion acquiring JenaValve, which targets aortic regurgitation, and Endotronix, which brings heart-failure monitoring into its ecosystem. These deals expand the addressable market beyond aortic stenosis. Combined with internal programs, they aim to sustain durable growth, though new indications and devices must clear regulatory and reimbursement hurdles before they contribute meaningfully.
The bear case: what would have to be true for $84.00
The most pessimistic published target is $84.00, -1.6% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Edwards Lifesciences is worth if the risks below bite instead of the drivers above.
Edwards faces several headwinds at once. TAVR growth has decelerated as the aortic-stenosis market matures, and competition from Medtronic's Evolut platform and Abbott's Navitor could erode share even after Boston Scientific's exit. Much of the business depends on favorable reimbursement and FDA decisions, so a delayed or narrowed label expansion (such as for asymptomatic patients) would hurt the growth story. The stock typically trades at a premium multiple, often well above the broad market, which leaves little margin for error if results disappoint. Finally, integrating acquisitions like JenaValve and Endotronix carries execution risk and may pressure near-term margins before the pipeline pays off.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding EW already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on EW
26 analysts cover EW, with an average target of $100.96 (+18.3% against $85.35) and a split of 21 buy, 7 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the EW forecast and price target page.
How is EW valued? (as of FY2025 results (year ended December 31, 2025) and early 2026 figures)
Snapshot for EW as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Total revenue (FY2025): ~$6.07 billion, up ~11.5%
- TAVR sales (FY2025): ~$4.49 billion, up ~9.3%
- TMTT growth (FY2025): ~+56%, to ~$551 million
- Adjusted EPS (FY2025): ~$2.56 to $2.62 range
- Gross margin: ~78%
- Market cap: ~$48 to $52 billion
- P/E ratio: ~36x to 49x (varies by basis)
Reading a high-quality medtech like Edwards means weighing durable growth and very high gross margins against a premium valuation. The market has historically paid a P/E well above the broad market for Edwards because of its structural-heart leadership and recurring procedure-driven demand. That premium cuts both ways: when growth stays strong the multiple looks justified, but any deceleration in TAVR or a TMTT stumble can compress the multiple quickly. Because Edwards pays no dividend, total return depends on revenue and earnings growth plus buybacks rather than income.
How do you decide if EW is a buy?
Rather than asking whether EW is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold EW indirectly through an index or sector ETF before adding more.
What would change your mind on EW
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: TAVR leadership and label expansion stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: edwards faces several headwinds at once fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the EW stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about EW against your real portfolio and see your actual exposure before deciding.
Investing in Edwards Lifesciences with AI
Connect the broker you already use and ask Walnut's AI how EW fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is EW a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on TAVR leadership and label expansion, with total revenue (fy2025) at ~$6.07 billion, up ~11.5%. The bear case rests on edwards faces several headwinds at once. Analysts covering it are spread from $84.00 to $110.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell EW?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Edwards faces several headwinds at once. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $84.00, -1.6% from the $85.35 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for EW?
+
TAVR leadership and label expansion. TAVR remains the core franchise, generating about $4.49 billion in 2025, up roughly 9.3% year over year, and Edwards held an estimated low-70s percent share of the U.S. The most optimistic analyst target on EW is $110.00, +28.9% from the $85.35 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for EW?
+
Edwards faces several headwinds at once. TAVR growth has decelerated as the aortic-stenosis market matures, and competition from Medtronic's Evolut platform and Abbott's Navitor could erode share even after Boston Scientific's exit. Much of the business depends on favorable reimbursement and FDA decisions, so a delayed or narrowed label expansion (such as for asymptomatic patients) would hurt the growth story. The stock typically trades at a premium multiple, often well above the broad market, which leaves little margin for error if results disappoint. Finally, integrating acquisitions like JenaValve and Endotronix carries execution risk and may pressure near-term margins before the pipeline pays off. The most pessimistic published target is $84.00, -1.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Edwards Lifesciences do?
+
The global leader in structural heart disease, best known for its SAPIEN TAVR valves and fast-growing transcatheter mitral and tricuspid therapies.
What would have to change for EW to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (TAVR leadership and label expansion) stalling in the reported numbers rather than in the narrative, the risk above (edwards faces several headwinds at once) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Edwards Lifesciences do?
+
Edwards Lifesciences makes devices that treat structural heart disease. Its flagship product is the SAPIEN transcatheter aortic valve, used in TAVR procedures that replace a diseased aortic valve through a catheter instead of open-heart surgery. It also sells transcatheter mitral and tricuspid repair and replacement systems (PASCAL, EVOQUE, SAPIEN M3) and traditional surgical heart valves to hospitals worldwide.
What is TAVR?
+
TAVR stands for transcatheter aortic valve replacement. It is a minimally invasive procedure that replaces a narrowed aortic valve by threading a new valve, such as Edwards' SAPIEN, through a catheter, usually via an artery in the leg, rather than opening the chest. TAVR is Edwards' largest business, generating about $4.49 billion in 2025, and the company is working to expand its use to asymptomatic patients.
Does EW pay a dividend?
+
No. Edwards Lifesciences does not pay a dividend. Instead it returns cash to shareholders through share buybacks, completing a roughly $500 million repurchase in early 2026 with about $1.5 billion remaining under its authorization. The company reinvests heavily in research, development, and acquisitions, so total return for shareholders comes from growth and buybacks rather than dividend income.
Walnut is informational, not investment advice, and gives no verdict on EW. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.